One Medical Developments International Insider Raised Stake By 42% In Previous Year
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
Over the last year, we can see that the biggest insider purchase was by insider David Williams for AU$3.3m worth of shares, at about AU$2.07 per share. That means that an insider was happy to buy shares at above the current price of AU$0.59. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was David Williams.
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
Check out our latest analysis for Medical Developments International
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Medical Developments International insiders own 15% of the company, worth about AU$9.7m. We do generally prefer see higher levels of insider ownership.
There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Medical Developments International stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 3 warning signs we've spotted with Medical Developments International (including 1 which is potentially serious).
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
30 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
The Hill
an hour ago
- The Hill
Bolivia heads to the polls as its right-wing opposition eyes first victory in decades
LA PAZ, Bolivia (AP) — Bolivians headed to the polls on Sunday to vote in presidential and congressional elections that could spell the end of the Andean nation's long-dominant leftist party and see a right-wing government elected for the first time in over two decades. The election on Sunday is one of the most consequential for Bolivia in recent times — and one of the most unpredictable. Even at this late stage, a remarkable 30% or so of voters remain undecided. Polls show the two leading right-wing candidates, multimillionaire business owner Samuel Doria Medina and former President Jorge Fernando 'Tuto' Quiroga, locked in a virtual dead heat. Many undecided voters But a right-wing victory isn't assured. Many longtime voters for the governing Movement Toward Socialism, or MAS, party, now shattered by infighting, live in rural areas and tend to be undercounted in polling. With the nation's worst economic crisis in four decades leaving Bolivians waiting for hours in fuel lines, struggling to find subsidized bread and squeezed by double-digit inflation, the opposition candidates are billing the race as a chance to alter the country's destiny. 'I have rarely, if ever, seen a situational tinderbox with as many sparks ready to ignite,' Daniel Lansberg-Rodriguez, founding partner of Aurora Macro Strategies, a New York-based advisory firm, writes in a memo. Breaking the MAS party's monopoly on political power, he adds, pushes 'the country into uncharted political waters amid rising polarization, severe economic fragility and a widening rural–urban divide.' Bolivia could follow rightward trend The outcome will determine whether Bolivia — a nation of about 12 million people with the largest lithium reserves on Earth and crucial deposits of rare earth minerals — follows a growing trend in Latin America, where right-wing leaders like Argentina's libertarian Javier Milei, Ecuador's strongman Daniel Noboa and El Salvador's conservative populist Nayib Bukele have surged in popularity. A right-wing government in Bolivia could trigger a major geopolitical realignment for a country now allied with Venezuela's socialist-inspired government and world powers such as China, Russia and Iran. Conservative candidates vow to restore US relations Doria Medina and Quiroga have praised the Trump administration and vowed to restore ties with the United States — ruptured in 2008 when charismatic, long-serving former President Evo Morales expelled the American ambassador. The right-wing front-runners also have expressed interest in doing business with Israel, which has no diplomatic relations with Bolivia, and called for foreign private companies to invest in the country and develop its rich natural resources. After storming to office in 2006 at the start of the commodities boom, Morales, Bolivia's first Indigenous president, nationalized the nation's oil and gas industry, using the lush profits to reduce poverty, expand infrastructure and improve the lives of the rural poor. After three consecutive presidential terms, as well as a contentious bid for an unprecedented fourth in 2019 that set off popular unrest and led to his ouster, Morales has been barred from this race by Bolivia's constitutional court. His ally-turned-rival, President Luis Arce, withdrew his candidacy for the MAS on account of his plummeting popularity and nominated his senior minister, Eduardo del Castillo. As the party splintered, Andrónico Rodríguez, the 36-year-old president of the senate who hails from the same union of coca farmers as Morales, launched his bid. Ex-president Morales urges supports to deface ballots Rather than back the candidate widely considered his heir, Morales, holed up in his tropical stronghold and evading an arrest warrant on charges related to his relationship with a 15-year-old girl, has urged his supporters to deface their ballots or leave them blank. Voting is mandatory in Bolivia, where some 7.9 million Bolivians are eligible to vote. Doria Medina and Quiroga, familiar faces in Bolivian politics who both served in past neoliberal governments and have run for president three times before, have struggled to stir up interest as voter angst runs high. 'There's enthusiasm for change but no enthusiasm for the candidates,' said Eddy Abasto, 44, a Tupperware vendor in Bolivia's capital of La Paz torn between voting for Doria Medina and Quiroga. 'It's always the same, those in power live happily spending the country's money, and we suffer.' Conservative candidates say austerity needed Doria Medina and Quiroga have warned of the need for a painful fiscal adjustment, including the elimination of Bolivia's generous food and fuel subsidies, to save the nation from insolvency. Some analysts caution this risks sparking social unrest. 'A victory for either right-wing candidate could have grave repercussions for Bolivia's Indigenous and impoverished communities,' said Kathryn Ledebur, director of the Andean Information Network, a Bolivian research group. 'Both candidates could bolster security forces and right-wing para-state groups, paving the way for violent crackdowns on protests expected to erupt over the foreign exploitation of lithium and drastic austerity measures.' All 130 seats in Bolivia's Chamber of Deputies, the lower house of Parliament, are up for grabs, along with 36 in the Senate, the upper house. If, as is widely expected, no one receives more than 50% of the vote, or 40% of the vote with a lead of 10 percentage points, the top two candidates will compete in a runoff on Oct. 19 for the first time since Bolivia's 1982 return to democracy.
Business Insider
an hour ago
- Business Insider
What's Driving the Wild Swings in Tilray Stock (TLRY)?
Shares of Tilray Brands (TLRY) kicked off last week on a positive note after President Donald Trump said he is considering a proposal to reclassify marijuana as a less dangerous drug. Nonetheless, the stock ended the week with a 10.5% drop on Friday. Overall, TLRY stock has gained nearly 35% over the past five trading days, though it remains down more than 30% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. For context, Tilray Brands produces and distributes cannabis, hemp-based foods, and alcoholic beverages across multiple markets. What's Behind TLRY's Moves? Speaking to reporters in the White House briefing room, Trump said the review of marijuana's classification is in progress, and a decision could come within the next few weeks. He added that he hopes the decision 'will be the right one.' The proposed change would move marijuana to Schedule III, which is a category for drugs with accepted medical uses and lower abuse potential. Right now, U.S. law classifies cannabis as a Schedule I drug under the Controlled Substances Act, putting it in the same category as highly dangerous drugs like heroin. Nonetheless, the proposal is currently under review by the U.S. Drug Enforcement Administration (DEA). Separately, Tilray confirmed it is seeking an extension from Nasdaq to regain listing compliance. This disclosure has likely fueled volatility and contributed to the price reversal on Friday. What Does It Mean for TLRY? If marijuana is reclassified as less dangerous, it could lift TLRY stock by easing rules for cannabis companies in the U.S. Such a change would ease restrictions, expand medical and commercial opportunities, and attract more investors. Overall, TLRY stock has remained volatile in the past year. However, a move of this size is rare even for Tilray, suggesting the news had a major impact on how the market views the company. Is TLRY a Good Buy? TLRY stock based on two Buys and four Holds assigned in the past three months. Furthermore, the average Tilray stock price target of $0.94 per share implies a downside of over 10% from the current level.
